Leerink raised target for McKesson stock to USD 1,070

Published on 10/14/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 105.38 billion in fiscal 2027. McKesson stock costs EUR 863.00 on October 14, 2026, 2.01 percent above Xetra close EUR 846.00.

Earnings and valuation markers

Leerink Partners raised its McKesson target to USD 1,070 on October 7, 2026.
Fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
McKesson stock trades at EUR 863.00 at 11:02 a.m. CEST at Lang & Schwarz on October 14, 2026, 2.01 percent above the Xetra close of October 13, 2026.
McKesson will publish second-quarter fiscal 2027 results on November 4, 2026.

Aquarellbild einer Skyline mit Bürotürmen am Fluss im Sonnenuntergangslicht — Aquarellmalerei zeigt eine Stadtsilhouette am Firmensitz-Standort von McKesson Corporation ISIN US58155Q1031 bei warmem Sonnenuntergangslicht heute, Illustration mit AI erstellt.

McKesson (ISIN US58155Q1031) is trading at EUR 863.00 at Lang & Schwarz on October 14, 2026 at 11:02 a.m. CEST, 2.01 percent above the Xetra close of October 13, 2026 at EUR 846.00. Leerink Partners raised its McKesson price target to USD 1,070 from USD 1,030 on October 7, 2026, according to MarketBeat.

Target rises as earnings hold up

The Leerink change kept an outperform rating and put the USD 1,070 objective above the USD 973.19 average target cited for McKesson by MarketBeat on October 8, 2026. The same report described 14 Buy ratings and four Hold ratings among 18 brokerages.

McKesson reported USD 105.38 billion of revenue in the first quarter of fiscal 2027, up 7.70 percent year over year, while adjusted earnings per share reached USD 9.93 versus a USD 9.56 consensus estimate, according to MarketBeat. The comparison matters because the latest target increase rests on both valuation expectations and operating momentum.

Three events shape the stock

On October 1, 2026, McKesson announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, according to McKesson. On October 5, 2026, McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for approximately USD 5.8 billion, with McKesson planning a USD 1.4 billion investment for a 49 percent stake, as reported by MarketBeat.

What comes next for earnings?

McKesson reaffirmed fiscal 2027 adjusted earnings-per-share guidance of USD 44.20 to USD 45.00 in its October 1 release. The company will publish second-quarter fiscal 2027 results after market close on November 4, 2026, with its conference call scheduled for 4:30 p.m. ET, according to McKesson Investor Relations. That date gives the market a defined test for the USD 44.20 to USD 45.00 outlook and the strategic spending attached to Option Care.

Stock trades above the Xetra close

At Lang & Schwarz, McKesson stock was trading at EUR 863.00 on October 14, 2026 at 11:02 a.m. CEST, up 2.01 percent versus the Xetra close of October 13, 2026 at EUR 846.00. The primary listing is on the NYSE, where the 52-week range was USD 723.68 to USD 999.00 and market capitalization was USD 112.6 billion as of October 13, 2026. The further course of trading is shown by the continuously updated real-time quote of McKesson stock.